Clinical Trial Results:
Multicenter, Single-arm Open-label Extension Study to Assess Long-term Safety and Efficacy of Current or Prior Treatment With Denosumab in Children/Young Adults With Osteogenesis Imperfecta
Summary
|
|
EudraCT number |
2018-000550-21 |
Trial protocol |
HU PL BE DE GB ES CZ FR BG IT |
Global end of trial date |
28 Mar 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Oct 2022
|
First version publication date |
12 Oct 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
20170534
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03638128 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Amgen Inc.
|
||
Sponsor organisation address |
One Amgen Center Drive, Thousand Oaks, CA, United States, 91320
|
||
Public contact |
IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
|
||
Scientific contact |
IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-000145-PIP02-12 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
28 Mar 2022
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
28 Mar 2022
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective was to evaluate long-term safety of denosumab in subjects with pediatric osteogenesis imperfecta (OI) who completed Study 20130173 (EudraCT Number: 2014-000184-40).
|
||
Protection of trial subjects |
This study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) regulations/guidelines.
The study protocol and all amendments, the informed consent form, and any accompanying materials provided to the subjects were reviewed and approved by an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) at each study center.
The investigator or his/her designee informed the subject of all aspects pertaining to the subject’s participation in the study before any screening procedures were performed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
26 Jul 2018
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
6 Months | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 3
|
||
Country: Number of subjects enrolled |
Czechia: 2
|
||
Country: Number of subjects enrolled |
France: 2
|
||
Country: Number of subjects enrolled |
Germany: 29
|
||
Country: Number of subjects enrolled |
Hungary: 4
|
||
Country: Number of subjects enrolled |
Italy: 6
|
||
Country: Number of subjects enrolled |
Poland: 1
|
||
Country: Number of subjects enrolled |
Spain: 3
|
||
Country: Number of subjects enrolled |
United Kingdom: 8
|
||
Country: Number of subjects enrolled |
Canada: 10
|
||
Country: Number of subjects enrolled |
United States: 7
|
||
Worldwide total number of subjects |
75
|
||
EEA total number of subjects |
50
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
24
|
||
Adolescents (12-17 years) |
42
|
||
Adults (18-64 years) |
9
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||
Recruitment details |
This study was conducted at 22 centers in North America, Europe, and Australia from July 2018 to March 2022. | ||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||
Screening details |
Subjects enrolled in Study 20130173 were eligible for this study if they completed Study 20130173 end of study visit, did not reconsent/reassent to transition to the Q3M dosing regimen, or early terminated due to meeting BMD Z-score investigational product stopping criteria. | ||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||
Period 1 title |
Open-label Extension (overall period)
|
||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||
Arm title
|
Alternative Medications / Observational | ||||||||||||||||||||||||||||
Arm description |
Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline. Alternative osteoporosis medication(s) were determined at the investigator’s discretion and per standard of care and local guidelines. | ||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||
Arm title
|
Denosumab 1 mg/kg Q6M | ||||||||||||||||||||||||||||
Arm description |
Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) administered by subcutaneous injection, but no Q3M denosumab during this study. | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Denosumab
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
AMG 162
|
||||||||||||||||||||||||||||
Other name |
Prolia®
|
||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Administered by subcutaneous injection once every 6 months
|
||||||||||||||||||||||||||||
Arm title
|
Denosumab 1 mg/kg Q3M | ||||||||||||||||||||||||||||
Arm description |
Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study. | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Denosumab
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
AMG 162
|
||||||||||||||||||||||||||||
Other name |
Prolia®
|
||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Administered by subcutaneous injection once every 3 months
|
||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Alternative Medications / Observational
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline. Alternative osteoporosis medication(s) were determined at the investigator’s discretion and per standard of care and local guidelines. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Denosumab 1 mg/kg Q6M
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) administered by subcutaneous injection, but no Q3M denosumab during this study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Denosumab 1 mg/kg Q3M
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Any Treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Participants who were enrolled in the study and received denosumab Q3M or Q6M, alternative treatment or did not receive any treatment.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Alternative Medications / Observational
|
||
Reporting group description |
Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline. Alternative osteoporosis medication(s) were determined at the investigator’s discretion and per standard of care and local guidelines. | ||
Reporting group title |
Denosumab 1 mg/kg Q6M
|
||
Reporting group description |
Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) administered by subcutaneous injection, but no Q3M denosumab during this study. | ||
Reporting group title |
Denosumab 1 mg/kg Q3M
|
||
Reporting group description |
Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study. | ||
Subject analysis set title |
Any Treatment
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Participants who were enrolled in the study and received denosumab Q3M or Q6M, alternative treatment or did not receive any treatment.
|
|
|||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Participants with Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest [1] | ||||||||||||||||||||||||||||||||||||||||||||
End point description |
Adverse events of special interest included changes in growth plate morphology, severe or symptomatic hypocalcemia, hypersensitivity, bacterial cellulitis, osteonecrosis of the jaw (ONJ), abnormal molar eruption, hypercalcemia, and abnormal mandibular shaping.
|
||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months.
|
||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study was descriptive in nature and did not involve testing formal hypotheses. |
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Number of Participants with Anti-denosumab Antibodies [2] [3] | |||||||||||||||
End point description |
Blood samples were collected (from denosumab treated subjects only) for the measurement of anti-denosumab binding antibodies. Samples positive for anti-denosumab binding antibodies were further tested for neutralizing antibodies.
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
|
|||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study was descriptive in nature and did not involve testing formal hypotheses. [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Participants in the Alternative Medications / Observational group were not tested for anti-denosumab antibodies. |
||||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Participants with Clinical Laboratory Toxicities Grade ≥ 3 [4] | ||||||||||||
End point description |
Laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. The grades refer to the severity of the finding:
Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening consequences, urgent intervention indicated.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
|
||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study was descriptive in nature and did not involve testing formal hypotheses. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Participants with Clinically Significant Vital Sign Findings [5] | ||||||||||||
End point description |
Vital sign measurements included systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature. The investigator assessed vital sign results and determined whether any abnormal changes represented a clinically significant change from the participant's baseline values.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
|
||||||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study was descriptive in nature and did not involve testing formal hypotheses. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Participants with Metaphyseal Index Z-score Above Age-appropriate Normal Range [6] | ||||||||||||||||||||||||
End point description |
Anteroposterior radiographs of both knees (unless prohibited by the presence of hardware such as implants) were used to calculate the metaphyseal index Z-score of each knee in participants with open growth plates; the knee selected for assessment during the study was the knee with the higher Z-score at baseline. The metaphyseal index (MI) was calculated by the central imaging vendor as the ratio of femoral width over distal femoral growth plate width, and the Z-score for each subject, relative to the subject’s age as:
MI Z-score = (subject value – mean)/SD, where mean and standard deviation (SD) are the corresponding values based on a reference population for the subject’s age group at the time of the assessment.
Metaphyseal index Z-score above age-appropriate normal range is defined as a MI Z-score > 2.
The metaphyseal analysis set includes subjects with open growth plates and no hardware preventing accurate calculation of MI at baseline and knee X-ray at baseline and postbaseline.
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Baseline, month 12 and month 24
|
||||||||||||||||||||||||
Notes [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study was descriptive in nature and did not involve testing formal hypotheses. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Notes [7] - Metaphyseal analysis set; subjects with available data at each time point [8] - Metaphyseal analysis set; subjects with available data at each time point [9] - Metaphyseal analysis set ; subjects with available data at each time point |
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Participants with Abnormal Molar Eruption of the First or Second Molar Based on Radiological Findings [10] | ||||||||||||||||||||||||
End point description |
Participants underwent a visual inspection under natural light for the presence of the first and second molars. Participants were referred to a dentist to perform radiographic assessment of the unerupted molar(s) if:
- A participant was age 7 to 12 years and appeared to have an unerupted upper or lower first molar (ie, not all 4 first molars were visible/detectable).
- A participant was age 13 years or older and appeared to have an unerupted upper or lower (first or) second molar (ie, not all 4 first molars and all 4 second molars were visible/detectable).
Abnormal molar eruptions includes the number of participants 7 to 12 years of age with 1st unerupted or partially erupted molars and participants 13 years of age or older with 2nd unerupted or partially erupted molars.
The analysis at each time point includes participants with radiologic assessments.
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Baseline, month 12, and month 24
|
||||||||||||||||||||||||
Notes [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study was descriptive in nature and did not involve testing formal hypotheses. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percent Change from Baseline in Mandibular Shaping Parameters [11] | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Lateral cephalogram was performed to enable assessment of mandibular shaping. The lateral cephalogram is a profile X-ray of the skull and soft tissues and is used to assess the relation of the teeth in the jaws, the relation of the jaws to the skull, and the relation of the soft tissues to the teeth and jaws.
The following anatomical angles and dimensions were measured to evaluate the correct proportions of the mandible and its position relative to the skull/maxilla: Gonial angle; Sella-Nasion-A Point Angle (SNA angle); Sella-Nasion-B Point Angle (SNB angle); and A Point - Nasion-B Point Angle (ANB Angle).
The analysis at each time point includes participants with radiologic assessments. "99999" indicates Not Applicable.
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and month 12 and month 24
|
||||||||||||||||||||||||||||||||||||||||||||||||
Notes [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study was descriptive in nature and did not involve testing formal hypotheses. |
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change from Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score | ||||||||||||||
End point description |
Bone densitometry assessments of the lumbar spine were performed using dual X-ray absorptiometry (DXA).
The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in lumbar spine BMD.
The DXA analysis set includes all subjects with baseline and ≥ 1 postbaseline valid DXA assessments for lumbar spine as provided by the central imaging vendor.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline and months 6, 12, and 24
|
||||||||||||||
|
|||||||||||||||
Notes [12] - DXA analysis set; subjects with available data at each time point |
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change from Baseline in Total Hip BMD Z-score | ||||||||||||||
End point description |
Bone densitometry assessments of the hip were performed using dual X-ray absorptiometry (DXA).
The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in total hip BMD.
The DXA analysis set includes all subjects with baseline and ≥ 1 postbaseline valid DXA assessments for the total hip as provided by the central imaging vendor.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline, months 6, 12, and 24
|
||||||||||||||
|
|||||||||||||||
Notes [13] - DXA analysis set; subjects with available data at each time point |
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change from Baseline in Femoral Neck BMD Z-score | ||||||||||||||
End point description |
Bone densitometry assessments of the femoral neck were performed using dual X-ray absorptiometry (DXA).
The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in femoral neck BMD.
The DXA analysis set includes all subjects with baseline and ≥ 1 postbaseline valid DXA assessments for the femoral neck as provided by the central imaging vendor.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline, month 6, 12, and 24
|
||||||||||||||
|
|||||||||||||||
Notes [14] - DXA analysis set; subjects with available data at each time point |
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
25.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Alternative Medications / Observational
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline. Alternative osteoporosis medication(s) were determined at the investigator’s discretion and per standard of care and local guidelines. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Denosumab 1 mg/kg Q3M
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Denosumab 1 mg/kg Q6M
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) administered by subcutaneous injection, but no Q3M denosumab during this study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
11 Jul 2019 |
Major changes to the protocol included:
• included incidence of adverse events of special interest in the primary endpoint.
• clarified the treatment options for the study.
• updated dose modification language. |
||
31 Mar 2020 |
Major changes to the protocol included:
• defined denosumab Q3M as the investigational product for the study.
• modified inclusion criteria to allow subjects who did not reconsent to transition to Q3M dosing regimen in Study 20130173, or early terminated from Study 20130173 due to meeting BMD Z-score investigational product stopping criteria.
• updated end of study definition.
• updated dose modification language. |
||
30 Apr 2020 |
Major changes to the protocol included:
• clarified that day 10 and day 30 assessments are only required for subjects who started the Q3M dosing regimen for the first time. |
||
17 Nov 2020 |
Major changes to the protocol included:
• added additional serum calcium samples at days 10 and 30 after investigational product dosing at weeks 12 and 24.
• updated definition of study day 1 and end of study. |
||
14 Jan 2021 |
Major changes to the protocol included:
• updated to harmonize content with Study 20130173 protocol after minor updates to Schedule of Activities and remove reference to the Safety Report Form. |
||
09 Nov 2021 |
Major updates to the protocol included:
• updated text throughout based on early study termination due to the risk of hypercalcemia.
• added immediate discontinuation of all subjects from study treatment followed by a 24-week safety follow-up period. |
||
02 Feb 2022 |
Major updates to the protocol included:
• removed the secondary efficacy endpoints of fracture and growth velocity.
• clarified that BMD Z-score and BTM will be assessed at 6, 12, and 24 months.
• removed the exploratory endpoint of BMD and bone mineral content.
• removed the subgroup analysis. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |